We came across a bullish thesis on Veeva Systems Inc. on Compound & Fire’s Substack by Compound & Fire. In this article, we will summarize the bulls’ thesis on VEEV. Veeva Systems Inc.’s share was trading at $240.14 as of December 2nd. VEEV’s trailing and forward P/E were 46.86 and 27.86 respectively according to Yahoo Finance.
Wichy/Shutterstock.com
Veeva Systems Inc. (VEEV) is a leading provider of cloud-based software solutions for the life sciences industry, offering an ecosystem that integrates data, software, and services. Founded in 2007 by Peter Gassner, a former Salesforce executive, Veeva initially launched with Veeva CRM built on Salesforce’s platform, rapidly establishing itself as a mission-critical tool for pharmaceutical sales teams.
Over time, the company expanded into clinical, regulatory, and quality solutions through its Veeva Vault platform, creating a comprehensive end-to-end suite that now supports most top global biopharma companies. Gassner, alongside COO Tom Schwenger, has cultivated a disciplined, long-term culture focused on customer success, innovation, and profitability, with no reliance on acquisitions for growth.
Veeva’s business model is subscription-based, providing high visibility and recurring revenue, complemented by professional services that enhance adoption and stickiness. The company operates across two main segments: Commercial Solutions, which include CRM and data offerings, and R&D Solutions, encompassing clinical, regulatory, and quality applications.
Its expansion into R&D has significantly increased its total addressable market, with large biopharma clients deeply integrated into Veeva’s ecosystem. The company’s culture emphasizes accountability, customer-centricity, and sustainable innovation, maintaining strong profitability with operating margins above 35%.
Strategically, Veeva is transitioning from Salesforce infrastructure to its proprietary Vault platform, ensuring full control and scalability across its solutions. This migration strengthens its moat, reduces platform dependency, and aligns its innovation roadmap. With long-term contracts, deep customer relationships, and a reputation for reliability, Veeva remains a structural winner in the digitization of life sciences, offering stable growth and resilience across market cycles.
Previously we covered a bullish thesis on Veeva Systems Inc. (VEEV) by Francesco Ferrari in March 2025, which highlighted its high-margin recurring revenue model and strong balance sheet. The company’s stock price has appreciated approximately by 0.20% since our coverage. The thesis still stands as Compound & Fire shares a similar view but emphasizes Veeva’s platform transition.
